Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Alexion Pharmaceuticals Inc (NASDAQ:ALXN)

126.07
Delayed Data
As of Jun 23
 -0.16 / -0.13%
Today’s Change
96.18
Today|||52-Week Range
145.42
+3.04%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$28.3B

Company Description

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products. Its products include soliris, strensiq and kanuma. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto and Leonard Bell in January 1992 and is headquartered in New Haven, CT.

Contact Information

Alexion Pharmaceuticals, Inc.
100 College Street
New Haven Connecticut 06510
P:(120) 320-3272
Investor Relations:
(203) 699-7722

Employees

Shareholders

Mutual fund holders58.57%
Other institutional40.33%
Individual stakeholders4.98%

Top Executives

Ludwig N. HantsonChief Executive Officer & Director
Julie O'NeillExecutive Vice President-Global Operations
Dave AndersonChief Financial Officer & Executive Vice President
Martin MacKayExecutive VP, Global Head-Research & Development
John J. OrloffExecutive VP & Head-Research & Development